F18 PSMA scanning. A disruptive change in prostate cancer care and management. Experience from Australasia

JOINT EVENT: 4^th International Conference and Exhibition on Medical Physics and Biophysics & 2^nd International Conference on Nuclear Medicine & Radiation Therapy

July 27-28, 2017 Rome, Italy

Trevor Fitz John

Pacific Radiology Ltd, New Zealand

Keynote: J Nucl Med Radiat Ther

Abstract :

The need for a distributable F18 based PSMA agent in New Zealand. I will present the distribution routes for Melbourne and Wellington based cyclotrons and pharmacy. I will review the first ~200 cases in this retrospective cohort from referrals by Urologists and Radiation Oncology with relation to disease case mix, and correlation with PSA and other imaging including 3T MRI of primary disease and 18F PET/CT bone scanning and body CT of disseminated disease. A subset of comparison of PSMA imaging against multiparametric mainly 3T MRI will be included. Representative slides will highlight points of interest.

Biography :

Trevor Fitz John obtained MBBS from Newcastle upon Tyne UK in 1978 followed by First FRCR examination in 1984. He immigrated to New Zealand in 1986. In NZ he has been at the forefront of technological advances being in the leading wave of establishing CT, MRI, PACS and most recently PET/CT at Pacific Radiology. He is the Chairman of Cyclotek Pharmaceuticals NZ which operates NZ’s only cyclotron. He has a keen interest in multimodality oncologic and neuro imaging.

Email: trevor.fitzjohn@pacificradiology.com